Showing 4641-4650 of 9847 results for "".
- DataDerm in Action: AAD Launches Project to Improve Outcomes for GPP Patientshttps://practicaldermatology.com/news/aad-launches-project-to-improve-outcomes-for-gpp-patients/2461804/The American Academy of Dermatology is launching a new project to develop educational resources to improve the evaluation, diagnosis, and treatment of patients with generalized pustular psoriasis (GPP). The AAD is working with Boehringer Ingelheim and using OM1’s data aggregation
- Potential Notalgia Paresthetica Breakthrough: Oral Difelikefalin May Curb Persistent Itchhttps://practicaldermatology.com/news/potential-notalgia-paresthetica-breakthrough-oral-difelikefalin-may-curb-persistent-itch/2461553/Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no U.S. Food and Drug Administration (FDA)-approved treatments specifically targeting this disorder. But a new s
- New Guidance Issued on Treating Metastatic Melanoma During COVID-19https://practicaldermatology.com/news/new-guidance-issued-on-treating-metastatic-melanoma-during-covid-19/2461497/Metastatic melanoma patients taking systemic therapy should stay on treatment whenever possible, even during Covid-19 pandemic. This is the main takeaway from new research paper in Oncotarget's
- Nevisense Improves Dermatologist’s Decision-making Beyond Dermoscopyhttps://practicaldermatology.com/news/nevisense-improves-dermatologists-decision-making-beyond-dermoscopy/2461403/SciBase’s Nevisense test provides benefit over standard of care visual and dermoscopic evaluation for biopsy decisions, according to a study in Melano
- Dr. Ida Orengo Named Chair of Department of Dermatology at Baylor College of Medicinehttps://practicaldermatology.com/news/dr-ida-orengo-named-chair-of-department-of-dermatology-at-baylor-college-of-medicine/2461384/Dr. Ida Orengo has been named chair of the Department of Dermatology at Baylor College of Medicine by the College’s Board of Trustees. Her appointment is effective Oct. 17. Dr. Ore
- Midmark Gives Back: Trade-in Program Results in Nearly 1,000 Exam Tables Donated to World Visionhttps://practicaldermatology.com/news/midmark-gives-back-trade-in-program-results-in-nearly-1000-exam-tables-donated-to-world-vision/2461347/Midmark Corp.'s 2021 trade-in program collected 1,000 eligible exam tables. The tables were donated primarily to World Vision, where they are refurbished and delivered to clinics that provide health c
- It’s Melanoma Monday! Focus on Preventionhttps://practicaldermatology.com/news/its-melanoma-monday-focus-on-prevention/2460792/With new data showing that one-third of Americans lack a basic understanding of skin cancer and sun protection, the American Academy of Dermatology’s annual Melanoma Monday takes on special significance.
- Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitishttps://practicaldermatology.com/news/etrasimod-performs-well-in-phase-phase-2b-trial-of-adult-atopic-dermatitis/2460761/Arena Pharmaceuticals, Inc.’s Etrasimod demonstrated statistical significance in both clinician and patient reported outcomes in atopic dermatitis, according to research presented at the American Academy of Dermatology VMX Experience. Etrasimod is an investigational, highly select
- Evelo's AD Candidate Meets Phase 1b Endpointshttps://practicaldermatology.com/news/evelos-ad-candidate-meets-phase-1b-endpoints/2460631/Evelo Biosciences, Inc.’s investigational atopic dermatitis treatment EDP1815 was well tolerated with no serious adverse events in a phase 1b clinical trial. According to the company, the oral drug candidate studied in 23 evaluable subjects with
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E